Privately-held CVRx Inc., developer of the Barostim Neo minimally invasive implantable system with separate indications for heart failure and resistant hypertension, has scored a major coup in securing $113 million in new funding in what remains a difficult market for medical device investment. The financing was led by Johnson & Johnson Development Corp., the venture arm of Johnson & Johnson.
Of equal significance, CVRx has also this year become one of the first beneficiaries of the US FDA’s Expedited Access...